171 related articles for article (PubMed ID: 32219539)
1. The implementation of health technology assessment principles in public decisions concerning orphan drugs.
Brenna E; Polistena B; Spandonaro F
Eur J Clin Pharmacol; 2020 Jun; 76(6):755-764. PubMed ID: 32219539
[TBL] [Abstract][Full Text] [Related]
2. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
3. An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
Kogushi K; Ogawa T; Ikeda S
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):455-471. PubMed ID: 31496361
[No Abstract] [Full Text] [Related]
4. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
5. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
6. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
7. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
8. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
9. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
10. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
11. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
12. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
13. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
14. HTA criteria adopted in different models of public healthcare systems for orphan drugs: A scoping review.
Felippini A; Biglia LV; Lima TM; Aguiar PM
Health Policy; 2024 Jun; 144():105080. PubMed ID: 38733643
[TBL] [Abstract][Full Text] [Related]
15. The Development of the Romanian Scorecard HTA System.
Radu CP; Chiriac ND; Pravat AM
Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
[TBL] [Abstract][Full Text] [Related]
16. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
Vostalová L; Mazelová J; Samek J; Vocelka M
Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
[TBL] [Abstract][Full Text] [Related]
17. Market uptake of orphan drugs--a European analysis.
Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
[TBL] [Abstract][Full Text] [Related]
18. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
[TBL] [Abstract][Full Text] [Related]
19. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
20. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]